Bone is continuously in a state of building and renewal, though the process of remodeling that takes place at many sites asynchronously throughout the skeleton, with bone formation and resorption equal at these sites (bone multicellular units). Remodeling takes place on bone surfaces, both on trabeculae and in the cortex, and serves the purposes of replacing old bone or that damaged by microfractures throughout the skeleton. The bone loss and consequent osteoporotic fractures that result from excess resorption over formation have mainly been prevented or treated by antiresorptive drugs that inhibit osteoclast formation and/or activity. Virtually all of the evidence leading to acceptance of antiresorptive drugs as treatment has depended upon their prevention of vertebral fractures. In recent decades, new prospects came of anabolic treatments that partly restore bone volume and microstructure restore bone that has been lost. The first of these was parathyroid hormone (PTH), shown by daily injection to increase markers of bone formation and prevent fractures. This field of interest enlarged with the discovery of PTH-related protein (PTHrP), so closely related in structure and action to PTH. The structural relationship between PTH and PTHrP is important in assessing their physiological and pharmacological roles, with the N-terminal domains of the 2 having virtually equal actions on target cells. Abaloparatide, a peptide analogue based on the structures of PTHrP and PTH, has been approved in some countries as a therapy for osteoporosis. Treatment through the PTH receptor activation pathway, and probably with any anabolic therapy, needs to be followed by antiresorptive treatment in order to maintain bone that has been restored. No matter how effective anabolic therapies for the skeleton become, it seems highly likely that there will be a continuing need for antiresorptive drugs.
Citations
Citations to this article as recorded by
A dual-active biological scaffold with in situ loaded Abaloparatide and bone marrow-derived mesenchymal stem cells synergistically regulatory T cell to promote bone regeneration Mingyu Jia, Zhihong Chen, Huajian Zhou, Haoran Jiang, Yukang Zhang, Yangyang Liu, Min Wu Biomaterials Advances.2026; 182: 214700. CrossRef
The Effects of Neonatal Zingerone Administration and Adolescent Alcohol Exposure on Bone Health Markers and Morphometry in Male Sprague–Dawley Rats Brunhildé De Vos, Bernice Asiedu, Anna M. Joubert, Abe E. Kasonga, Trevor T. Nyakudya, Baisakhi Banerjee BioMed Research International.2026;[Epub] CrossRef
Sex-specific hormonal rescue of bone growth in PAPPA2-deficient mice María del Mar Fernández-Arjona, Antonio J. López-Gambero, Leticia Rubio, Miguel Rodríguez-Pozo, Patricia Rivera, Marialuisa de Ceglia, Antonio Vargas, Fernando Rodríguez de Fonseca, Julie A. Chowen, Jesús Argente, Juan Suárez Bone & Joint Research.2026; 15(5): 519. CrossRef
Bone remodeling: a central mechanism in prostate cancer bone metastasis Hao Tang, Jun Chen, Honghan Wu, Yuanhao Lv, Qingde Wa, Sisi He PeerJ.2026; 14: e21344. CrossRef
Comparative Analysis of Romosozumab Versus Vertebroplasty With Denosumab: Efficacy, Safety, and Secondary Bone Mineral Density Outcomes Hyun Woong Mun, Jong Joo Lee, Hyun Chul Shin, Tae-Hwan Kim, Seok Woo Kim, Jae Keun Oh Neurospine.2025; 22(1): 69. CrossRef
Propensity Score Matching Analysis on Risk Factors and Their Diagnostic Value of Frailty in Elderly Patients With Cerebral Infarction Weiqi Gong, Wenlong Yuan, Miaomiao Zhai, Hua Jiang The Neurologist.2025; 30(5): 285. CrossRef
Antibody-Free Inline Dual-Retention Nano-WCX-μSPE-MS/MS for Quantification of Intact Parathyroid Hormone and Antagonistic Fragments in Clinical Serum Anping Wang, Jinlan Yang, Siqi Zhao, Yanyan Li, Li Yang, Xinhua Guo Analytical Chemistry.2025; 97(42): 23165. CrossRef
Advances in assessment and treatment of bone, mineral and parathyroid disorders Samuel D. Vasikaran Current Opinion in Endocrinology, Diabetes & Obesity.2024; 31(4): 139. CrossRef
Promotion of Bone Formation in a Rat Osteoporotic Vertebral Body Defect Model via Suppression of Osteoclastogenesis by Ectopic Embryonic Calvaria Derived Mesenchymal Stem Cells Yerin Yu, Somin Lee, Minsung Bock, Seong Bae An, Hae Eun Shin, Jong Seop Rim, Jun-oh Kwon, Kwang-Sook Park, Inbo Han International Journal of Molecular Sciences.2024; 25(15): 8174. CrossRef
Bone Mineral Density, C-Terminal Telopeptide of Type I Collagen, and Osteocalcin as Monitoring Parameters of Bone Remodeling in CML Patients Undergoing Imatinib Therapy: A Basic Science and Clinical Review Nurita Indarwulan, Merlyna Savitri, Ami Ashariati, Siprianus Ugroseno Yudho Bintoro, Muhammad Noor Diansyah, Putu Niken Ayu Amrita, Pradana Zaky Romadhon Diseases.2024; 12(11): 275. CrossRef
From the Editor-in-Chief: Featured Articles in the December 2023 Issue Inbo Han Neurospine.2023; 20(4): 1093. CrossRef
Cellular Basis for Sequencing of Antiresorptive and Anabolic Therapies for Bone: Commentary on “Bone Remodeling and Modeling: Cellular Targets for Antiresorptive and Anabolic Treatments, Including Approaches Through the Parathyroid Hormone (PTH)/PTH-Relat Natalie A. Sims Neurospine.2023; 20(4): 1110. CrossRef
First
Prev
